Post
of 40,799
The abstracts highlight research related to $BCTX cellular immunotherapy platform, including its ongoing Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor and its Bria-OTS+ personalized off-the-shelf immunotherapy program. https://globenewswire.com/news-release/2026/0...eting.html